Found 37 matching trials
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer N/A This is a multi-center biomarkers study aiming to prospectively collect bio...
Show More Location
Hospital Santo Stefano
Learn More & Join Trial
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line PHASE3 This study is designed to evaluate the efficacy and safety of first-line tr...
Show More Location
Gemeinschaftspraxis fĂŒr HĂ€matologie und Onkologie
Learn More & Join Trial
Chemo-free in Older (â„65) Node-Positive ER+/HER2- Breast Cancer PHASE3 This study is a prospective, open-label, multicenter, randomized controlled...
Show More Location
Multiple Locations
Learn More & Join Trial
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor PHASE3 This is a prospective, randomized, open-label, multicenter phase III study ...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3 Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather t...
Show More Status
Active Not Recruiting
Location
Jeroen Bosch Ziekenhuis
Learn More & Join Trial
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer PHASE3 This phase 3 clinical trial compares the efficacy and safety of palazestran...
Show More Location
Clinical Trial Site
Learn More & Join Trial
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. PHASE2 This was a randomized, double-blind, placebo-controlled study conducted in ...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer N/A Observational, longitudinal (retrospective cohort), multicenter, national s...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia N/A This prospective, observational, multicenter study aims at evaluating the e...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer PHASE1 The primary objective of Phase 1b will be to evaluate the safety and tolera...
Show More Location
Holy Cross Health Fort Lauderdale - Holy Cross Hospital
Learn More & Join Trial